文献速递淋巴瘤

RELIANCE研究中瑞基奥仑赛治疗复发或难治性滤泡性淋巴瘤的两年随访

Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
PubMed 文献 · Br J Haematol · 2025-09-01

RELIANCE研究评估瑞基奥仑赛(relma-cel)用于≥3线治疗的复发或难治性滤泡性淋巴瘤(R/R FL),患者28例,中位随访24.4个月;3个月完全缓解率85.2%、总缓解率100.0%,估计2年无进展生存率和总生存率分别为80.3%和100%,未出现新的安全性信号。

要点

  • 28例R/R FL患者接受瑞基奥仑赛,中位随访24.4个月,中位缓解持续时间、无进展生存和总生存均未达到。
  • 估计2年无进展生存率为80.3%,2年总生存率为100%。
  • 90天治疗中出现期无≥3级细胞因子释放综合征,≥3级神经毒性仅1例(100×10^6 CAR-T细胞),无导致死亡的AE。

核心结论

  • 瑞基奥仑赛在R/R FL患者2年随访中显示持久缓解和可控的安全性,未出现新的安全性信号。

研究设计与样本

  • RELIANCE研究(ClinicalTrials.gov,NCT04089215)纳入28例接受瑞基奥仑赛治疗的R/R FL患者,中位年龄54岁(范围36-71岁),超过60%的患者接受过≥3线既往系统性治疗,中位随访24.4个月。

主要发现

  • 在主要分析集(n=27)中,3个月完全缓解率为85.2%,3个月总缓解率为100.0%。
  • 中位缓解持续时间、中位无进展生存和中位总生存均未达到;估计2年无进展生存率为80.3%,估计2年总生存率为100%。
  • 在90天治疗中出现期(N=28),无患者发生≥3级细胞因子释放综合征,≥3级神经毒性仅见于1例接受100×10^6嵌合抗原受体T细胞治疗的患者。
  • 中性粒细胞减少(39.3%)是最常见的≥3级治疗中出现的不良事件;无导致死亡的不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relmacabtagene autoleucel (relma-cel) demonstrated significant clinical outcomes for ≥3 lines of treatment for relapsed or refractory (R/R) follicular lymphoma (FL) in the RELIANCE study. The primary end-point was the complete response rate (CRR) at 3 months. Key secondary end-points included the duration of response (DOR), progression-free survival (PFS), overall survival (OS) and frequency/severity of adverse events (AEs). Relma-cel-treated patients (N = 28) had a median age of 54 years (range: 36-71 years), and more than 60% of the patients received ≥3 lines of prior systemic therapies. The median follow-up was 24.4 months. As previously reported, in the primary analyses set (n = 27), the 3-month CRR was 85.2% and the 3-month overall response rate was 100.0%. The median DOR, PFS and OS were not reached. As updated in this article, the estimated 2-year PFS and OS rates were 80.3% and 100% respectively. During the 90-day treatment-emergent period (N = 28), no patients had cytokine release syndrome of grade ≥3, and neurological toxicity of grade ≥3 occurred in only one patient treated with 100 × 106 chimeric antigen receptor T cells. Neutropenia (39.3%) was the most common grade ≥3 treatment-emergent adverse event. There were no AEs leading to death. Relma-cel demonstrated durable remissions and manageable safety without new safety signals during the 2-year follow-up in patients with R/R FL (ClinicalTrials.gov, NCT04089215).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Song Y, Zou D, Yang H, et al. Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study. Br J Haematol. 2025. PMID: 40888120. doi:10.1111/bjh.20122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。